Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. This represented the first FDA-approved cellularized scaffold to apply tissue engineering processes for growth of cells on scaffolds using healthy autologous cartilage.
Sources: Vericel Corporation; ORTHOWORLD Inc.
Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults....
Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. This represented the first FDA-approved cellularized scaffold to apply tissue engineering processes for growth of cells on scaffolds using healthy autologous cartilage.
Sources: Vericel Corporation; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.